Acceleration of Tooth Movement Using PRP and Photobiomodulation With Clear Aligners

August 26, 2026 updated by: Arij Lutf Abdulrhman Abdul Majid, Sana'a University

Evaluation and Comparison of Acceleration of Tooth Movement Using Platelet-Rich Plasma (PRP) and Photobiomodulation (PBM) With Clear Orthodontic Appliances (Aligners): A Randomized Controlled Clinical Trial

This study compares the effectiveness of two adjunct therapies- photobiomodulation (low-level laser therapy) (PBM) and localized platelet-rich plasma (PRP) injections in accelerating orthodontic tooth movement. Participants receiving clear aligner therapy will be randomly assigned to one of three groups: clear aligners with PBM, clear aligners with PRP, or clear aligners alone (control group). The goal is to evaluate the efficiency, tooth movement tracking and safety.

Study Overview

Detailed Description

This randomized controlled clinical trial evaluates the acceleration orthodontic tooth movement using two adjunct biological stimulation modalities in patients under going clear aligners therapy participant are allocated into three groups:

  1. Clear aligner + photobiomodulation (PBM) : receives low-level laser therapy at specific intervals to stimulate cellular turnover and bone remodeling
  2. Clear aligner +platelet-rich plasma (PRP) :receives localized autologous injections in the target tooth movement area to facilitate biological response
  3. Clear aligners alone: (control group )receiving standard clear aligners treatment without additional interventions.

Outcomes will be evaluated periodically using digital intra-oral scanning to measure tracking, accuracy, rate of orthodontic tooth movement, and soft tissue - periodontal health throughout the active treatment period.

Study Type

Interventional

Enrollment (Estimated)

42

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Sanaa Governorate
      • Sanaa, Sanaa Governorate, Yemen, 009671
        • Faculty of Dentistry Sanaa university

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age 18- 25 years requiring clear aligner therapy
  • good oral hygiene and health periodontal status
  • full permanent dentition (excluding third molars)
  • willingness to comply with clear aligner wear schedules and follow -up visits.

Exclusion Criteria:

  • history of previous orthodontic treatment
  • Systemic diseases or conditions affecting bone metabolism
  • Ongoing pharmacological treatment able to influence orthodontic movement (e.g. prostaglandin inhibitors or biphosphonates)
  • Active periodontal disease or poor oral hygiene
  • history of photosensitivity or diseases triggered by light exposure
  • contraindication to PRP blood extraction

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Clear Aligner + Photobiomodulation
under a reduced wear-time framework.
extra-oral application of photobiomodulation (PBM) Therapy to the targeted alveolar site to evaluate its clinical effectiveness in accelerating orthodontic tooth movement
Clear aligner worn for 22-hour on the first day of each aligner stage, followed by a daily wear duration of 12-hour per day for the remaining period in combination with acceleration modalities
Experimental: Clear Aligner + Plasma Injection
under a reduced wear-time framework
Clear aligner worn for 22-hour on the first day of each aligner stage, followed by a daily wear duration of 12-hour per day for the remaining period in combination with acceleration modalities
local submucosal injection of Autologous Platelet Rich Plasma (PRP) into the targeted alveolar site to evaluate its clinical effectiveness in accelerating orthodontic tooth movement
Active Comparator: Clear Aligner Control Group
without any accelerator intervention
Clear aligners worn for the standard conventional duration of 22-hour per day without additional acceleration interventions

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of clinical tooth movement via intraoral digital scans
Time Frame: Every 4 weeks from baseline up to 6 months
Quantitative measurement of cumulative linear displacement and dental crown movement (in millimeters) calculated after every 2- aligners sequence (every 4 weeks) measurement will be obtained using digital intra-oral scan superimposed across all three study groups.
Every 4 weeks from baseline up to 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Root apex displacement
Time Frame: Baseline and 6 months
Assessment of root apex displacement in millimeters using CBCT superimposition
Baseline and 6 months
Patient-Reported Pain Level
Time Frame: At baseline, 24 hours, 48 hours, day 3, day 7 and day at aligner change up to 6 months.
Pain intensity is evaluated using the Visual Analog Scale from 0 to 10, where 0 indicates no pain and 10 represents the worst possible pain. Higher scores indicate worse pain.
At baseline, 24 hours, 48 hours, day 3, day 7 and day at aligner change up to 6 months.
Root resorption
Time Frame: Baseline and 6 months
Assessment of root resorption in millimeters using CBCT superimposition
Baseline and 6 months
Peri-tooth alveolar bone density
Time Frame: Baseline and 6 months
Assessment of peri-tooth alveolar bone density changes in Hounsfield Unit (HU) using CBCT superimposition.
Baseline and 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Arij L Abdulmajid, MSc, Sanaa University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

May 1, 2027

Study Registration Dates

First Submitted

August 17, 2026

First Submitted That Met QC Criteria

August 26, 2026

First Posted (Actual)

August 31, 2026

Study Record Updates

Last Update Posted (Actual)

August 31, 2026

Last Update Submitted That Met QC Criteria

August 26, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe